Cardiology clinical trial participation in community-based healthcare systems: obstacles and opportunities.

PubWeight™: 0.91‹?›

🔗 View Article (PMC 2615791)

Published in Contemp Clin Trials on March 04, 2008

Authors

Carol P Somkin1, Andrea Altschuler, Lynn Ackerson, Dennis Tolsma, Sharon J Rolnick, Robert Yood, W Douglas Weaver, Ann Von Worley, Mark Hornbrook, David J Magid, Alan S Go

Author Affiliations

1: Division of Research, Kaiser Permanente Northern California, Oakland, California, USA.

Articles cited by this

Response rates to mail surveys published in medical journals. J Clin Epidemiol (1997) 21.55

Practical clinical trials: increasing the value of clinical research for decision making in clinical and health policy. JAMA (2003) 14.72

Representation of elderly persons and women in published randomized trials of acute coronary syndromes. JAMA (2001) 4.28

Designing a mixed methods study in primary care. Ann Fam Med (2004) 3.89

Enrollment of women in cardiovascular clinical trials funded by the National Heart, Lung, and Blood Institute. N Engl J Med (2000) 3.76

Reported outcomes in major cardiovascular clinical trials funded by for-profit and not-for-profit organizations: 2000-2005. JAMA (2006) 3.65

Underrepresentation of renal disease in randomized controlled trials of cardiovascular disease. JAMA (2006) 2.22

The role of research in integrated healthcare systems: the HMO Research Network. Am J Manag Care (2004) 1.60

Organizational barriers to physician participation in cancer clinical trials. Am J Manag Care (2005) 1.56

Lessons learned from a clinical trial. Circulation (2004) 1.46

A clinical research strategy to support shared decision making. Health Aff (Millwood) (2005) 1.44

Sex differences in perceived risks, distrust, and willingness to participate in clinical trials: a randomized study of cardiovascular prevention trials. Arch Intern Med (2007) 1.12

Discovering the full spectrum of cardiovascular disease: Minority Health Summit 2003: executive summary. Circulation (2005) 1.11

Creating a culture of research. Contemp Clin Trials (2007) 1.03

Curbing the cardiovascular disease epidemic: aligning industry, government, payers, and academics. Health Aff (Millwood) (2007) 0.92

Patient recruitment: the costly and growing bottleneck in drug development. Drug Discov Today (2002) 0.92

Willingness to participate in cardiac trials. Am J Geriatr Cardiol (2004) 0.91

Efforts needed to foster participation of blacks in stroke studies. JAMA (2004) 0.90

Influence of clinical trial enrollment on the quality of care and outcomes for patients with non-ST-segment elevation acute coronary syndromes. Am Heart J (2005) 0.88

Perspectives on large-scale cardiovascular clinical trials for the new millennium. The Virtual Coordinating Center for Global Collaborative Cardiovascular Research (VIGOUR) Group. Circulation (1997) 0.84

Help wanted: participants for clinical trials. JAMA (2003) 0.79

A cooperative network of trained sites for the conduct of a complex clinical trial: a new concept in multicenter clinical research. Am Heart J (2006) 0.79

Articles by these authors

Heart disease and stroke statistics--2012 update: a report from the American Heart Association. Circulation (2011) 31.98

Heart disease and stroke statistics--2013 update: a report from the American Heart Association. Circulation (2012) 30.79

Heart disease and stroke statistics--2011 update: a report from the American Heart Association. Circulation (2010) 30.07

Heart disease and stroke statistics--2014 update: a report from the American Heart Association. Circulation (2013) 28.02

Heart disease and stroke statistics--2015 update: a report from the American Heart Association. Circulation (2014) 22.74

Heart Disease and Stroke Statistics-2016 Update: A Report From the American Heart Association. Circulation (2015) 10.14

Population trends in the incidence and outcomes of acute myocardial infarction. N Engl J Med (2010) 8.28

Strategies for reducing the door-to-balloon time in acute myocardial infarction. N Engl J Med (2006) 8.18

Criteria for evaluation of novel markers of cardiovascular risk: a scientific statement from the American Heart Association. Circulation (2009) 8.11

A pragmatic-explanatory continuum indicator summary (PRECIS): a tool to help trial designers. J Clin Epidemiol (2009) 7.86

The Chronic Renal Insufficiency Cohort (CRIC) Study: Design and Methods. J Am Soc Nephrol (2003) 7.79

Large-scale association analysis identifies new risk loci for coronary artery disease. Nat Genet (2012) 7.59

Body mass index and risk for end-stage renal disease. Ann Intern Med (2006) 7.56

Effect of medication nonadherence on hospitalization and mortality among patients with diabetes mellitus. Arch Intern Med (2006) 7.54

FGF23 induces left ventricular hypertrophy. J Clin Invest (2011) 7.22

Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. N Engl J Med (2003) 6.70

Executive summary: heart disease and stroke statistics--2014 update: a report from the American Heart Association. Circulation (2014) 6.55

Executive summary: heart disease and stroke statistics--2012 update: a report from the American Heart Association. Circulation (2012) 6.24

Executive summary: heart disease and stroke statistics--2013 update: a report from the American Heart Association. Circulation (2013) 6.13

Dialysis-requiring acute renal failure increases the risk of progressive chronic kidney disease. Kidney Int (2009) 5.28

Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest (2012) 5.27

Hospital quality for acute myocardial infarction: correlation among process measures and relationship with short-term mortality. JAMA (2006) 5.06

A new risk scheme to predict warfarin-associated hemorrhage: The ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study. J Am Coll Cardiol (2011) 5.06

Building a research consortium of large health systems: the Cancer Research Network. J Natl Cancer Inst Monogr (2005) 4.92

The net clinical benefit of warfarin anticoagulation in atrial fibrillation. Ann Intern Med (2009) 4.71

Impact of medication therapy discontinuation on mortality after myocardial infarction. Arch Intern Med (2006) 4.44

Appropriateness of percutaneous coronary intervention. JAMA (2011) 4.33

Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation. Ann Intern Med (2010) 4.16

Chronic Renal Insufficiency Cohort (CRIC) Study: baseline characteristics and associations with kidney function. Clin J Am Soc Nephrol (2009) 4.16

Health literacy and outcomes among patients with heart failure. JAMA (2011) 4.13

Effect of door-to-balloon time on mortality in patients with ST-segment elevation myocardial infarction. J Am Coll Cardiol (2006) 4.11

Renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: validation of the R(2)CHADS(2) index in the ROCKET AF (Rivaroxaban Once-daily, oral, direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (AnTicoagulation and Risk factors In Atrial fibrillation) study cohorts. Circulation (2012) 4.10

Incidence of death and acute myocardial infarction associated with stopping clopidogrel after acute coronary syndrome. JAMA (2008) 4.06

Risk factors for end-stage renal disease: 25-year follow-up. Arch Intern Med (2009) 4.05

Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest (2008) 4.01

Reducing delay in seeking treatment by patients with acute coronary syndrome and stroke: a scientific statement from the American Heart Association Council on cardiovascular nursing and stroke council. Circulation (2006) 3.93

Improved blood pressure control associated with a large-scale hypertension program. JAMA (2013) 3.80

Importance of therapy intensification and medication nonadherence for blood pressure control in patients with coronary disease. Arch Intern Med (2008) 3.68

A pragmatic-explanatory continuum indicator summary (PRECIS): a tool to help trial designers. CMAJ (2009) 3.65

A conceptual model of emergency department crowding. Ann Emerg Med (2003) 3.52

A randomized trial of transfer for primary angioplasty versus on-site thrombolysis in patients with high-risk myocardial infarction: the Air Primary Angioplasty in Myocardial Infarction study. J Am Coll Cardiol (2002) 3.52

Prevention of atrial fibrillation: report from a national heart, lung, and blood institute workshop. Circulation (2009) 3.50

Racial and ethnic differences in time to acute reperfusion therapy for patients hospitalized with myocardial infarction. JAMA (2004) 3.45

Medication nonadherence is associated with a broad range of adverse outcomes in patients with coronary artery disease. Am Heart J (2008) 3.40

Practical clinical trials for translating research to practice: design and measurement recommendations. Med Care (2005) 3.38

Geographic variation in cardiovascular procedure use among Medicare fee-for-service vs Medicare Advantage beneficiaries. JAMA (2013) 3.30

Nonrecovery of kidney function and death after acute on chronic renal failure. Clin J Am Soc Nephrol (2009) 3.28

Prognostic significance of the change in glucose level in the first 24 h after acute myocardial infarction: results from the CARDINAL study. Eur Heart J (2006) 3.14

Antithrombotic therapy in atrial fibrillation: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest (2004) 3.11

Advanced age, anticoagulation intensity, and risk for intracranial hemorrhage among patients taking warfarin for atrial fibrillation. Ann Intern Med (2004) 3.06

Confirmation of a heart failure epidemic: findings from the Resource Utilization Among Congestive Heart Failure (REACH) study. J Am Coll Cardiol (2002) 3.05

Incidence and prognosis of resistant hypertension in hypertensive patients. Circulation (2012) 2.99

Comparison of risk stratification schemes to predict thromboembolism in people with nonvalvular atrial fibrillation. J Am Coll Cardiol (2008) 2.93

Elevated blood pressure and risk of end-stage renal disease in subjects without baseline kidney disease. Arch Intern Med (2005) 2.90

Darapladib for preventing ischemic events in stable coronary heart disease. N Engl J Med (2014) 2.90

Executive Summary: Heart Disease and Stroke Statistics-2016 Update: A Report From the American Heart Association. Circulation (2016) 2.87

Comparison of clinical interpretation with visual assessment and quantitative coronary angiography in patients undergoing percutaneous coronary intervention in contemporary practice: the Assessing Angiography (A2) project. Circulation (2013) 2.81

Effects of exam-room computing on clinician-patient communication: a longitudinal qualitative study. J Gen Intern Med (2005) 2.77

ADHD medications and risk of serious cardiovascular events in young and middle-aged adults. JAMA (2011) 2.77

Association of neighborhood characteristics with bystander-initiated CPR. N Engl J Med (2012) 2.75

International variation in and factors associated with hospital readmission after myocardial infarction. JAMA (2012) 2.75

Susceptibility locus for clinical and subclinical coronary artery disease at chromosome 9p21 in the multi-ethnic ADVANCE study. Hum Mol Genet (2008) 2.71

Racial variation in the prevalence of atrial fibrillation among patients with heart failure: the Epidemiology, Practice, Outcomes, and Costs of Heart Failure (EPOCH) study. J Am Coll Cardiol (2004) 2.68

Comparative effectiveness of patient education methods for type 2 diabetes: a randomized controlled trial. Arch Intern Med (2011) 2.66

Use of antidepressant medications during pregnancy: a multisite study. Am J Obstet Gynecol (2007) 2.61

Transplant nephrectomy improves survival following a failed renal allograft. J Am Soc Nephrol (2009) 2.56

Incident atrial fibrillation and risk of end-stage renal disease in adults with chronic kidney disease. Circulation (2012) 2.56

Health-related quality of life and estimates of utility in chronic kidney disease. Kidney Int (2005) 2.54

Commonly used surrogates for baseline renal function affect the classification and prognosis of acute kidney injury. Kidney Int (2009) 2.53

An effective approach to high blood pressure control: a science advisory from the American Heart Association, the American College of Cardiology, and the Centers for Disease Control and Prevention. J Am Coll Cardiol (2013) 2.47

Acute coronary care in the elderly, part I: Non-ST-segment-elevation acute coronary syndromes: a scientific statement for healthcare professionals from the American Heart Association Council on Clinical Cardiology: in collaboration with the Society of Geriatric Cardiology. Circulation (2007) 2.42

Validation of a new brief physical activity survey among men and women aged 60-69 years. Am J Epidemiol (2006) 2.37

Acute coronary care in the elderly, part II: ST-segment-elevation myocardial infarction: a scientific statement for healthcare professionals from the American Heart Association Council on Clinical Cardiology: in collaboration with the Society of Geriatric Cardiology. Circulation (2007) 2.30

Risks for end-stage renal disease, cardiovascular events, and death in Hispanic versus non-Hispanic white adults with chronic kidney disease. J Am Soc Nephrol (2006) 2.26

Early statin initiation and outcomes in patients with acute coronary syndromes. JAMA (2002) 2.23

Risk of heart failure in breast cancer patients after anthracycline and trastuzumab treatment: a retrospective cohort study. J Natl Cancer Inst (2012) 2.21

Low frequency of treatment of osteoporosis among postmenopausal women following a fracture. Arch Intern Med (2003) 2.19

Death and disability from warfarin-associated intracranial and extracranial hemorrhages. Am J Med (2007) 2.16

ACC/AHA clinical performance measures for adults with ST-elevation and non-ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures (Writing Committee to Develop Performance Measures on ST-Elevation and Non-ST-Elevation Myocardial Infarction). Circulation (2006) 2.12

Associations between kidney function and subclinical cardiac abnormalities in CKD. J Am Soc Nephrol (2012) 2.10

Pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to primary percutaneous coronary intervention in acute myocardial infarction: the COMplement inhibition in Myocardial infarction treated with Angioplasty (COMMA) trial. Circulation (2003) 2.09

Procedural complications, rehospitalizations, and repeat procedures after catheter ablation for atrial fibrillation. J Am Coll Cardiol (2012) 2.05

Oral ximelagatran for secondary prophylaxis after myocardial infarction: the ESTEEM randomised controlled trial. Lancet (2003) 2.04

Effects of short daily versus conventional hemodialysis on left ventricular hypertrophy and inflammatory markers: a prospective, controlled study. J Am Soc Nephrol (2005) 2.04

Trends in reperfusion strategies, door-to-needle and door-to-balloon times, and in-hospital mortality among patients with ST-segment elevation myocardial infarction enrolled in the National Registry of Myocardial Infarction from 1990 to 2006. Am Heart J (2008) 2.04

The Cardiovascular Research Network: a new paradigm for cardiovascular quality and outcomes research. Circ Cardiovasc Qual Outcomes (2008) 2.03

Chronic kidney disease and cognitive function in older adults: findings from the chronic renal insufficiency cohort cognitive study. J Am Geriatr Soc (2010) 2.03

Safety climate and medical errors in 62 US emergency departments. Ann Emerg Med (2012) 2.02

President's page: The continuing importance of international engagement. J Am Coll Cardiol (2008) 2.01

Characterizing the admixed African ancestry of African Americans. Genome Biol (2009) 2.01

Cost-effectiveness of using high-sensitivity C-reactive protein to identify intermediate- and low-cardiovascular-risk individuals for statin therapy. Circulation (2010) 2.00

Prevalence of osteonecrosis of the jaw in patients with oral bisphosphonate exposure. J Oral Maxillofac Surg (2009) 2.00

Medication errors among adults and children with cancer in the outpatient setting. J Clin Oncol (2008) 2.00